Bristol Antidiabetic Carcinogenicity Data Look Clean; NDA Filing By Year-End?

With 80% of data reported, Bristol has "not seen anything that would concern us" about muraglitazar. NDA would be the first in the dual PPAR class after repeated development failures for similar compounds.